Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Israels Intec Pharma eyes revenue from Parkinsons drug in 2019

      Israel's Intec Pharma eyes revenue from Parkinson's drug in 2019

      Medical Dialogues Bureau11 Nov 2018 9:40 AM IST
      New Delhi: Tel Aviv, Israel's Intec Pharma, which is conducting a late-stage trial for its long-lasting pill to treat Parkinson's disease, expects to...
      AstraZeneca returns to sales growth, led by cancer medicines

      AstraZeneca returns to sales growth, led by cancer medicines

      Medical Dialogues Bureau11 Nov 2018 9:00 AM IST
      LONDON: Strong demand for AstraZeneca's new drugs - especially those for cancer - drove a return to sales growth in the third quarter and the...
      US FDA to strictly monitor sale of flavoured e-cigarettes

      US FDA to strictly monitor sale of flavoured e-cigarettes

      Medical Dialogues Bureau10 Nov 2018 3:46 PM IST
      The new policy will apply to flavoured cartridge-style vaping products like Juul that have become popular among youths, not the open tank-style...
      Fortis Q2 net loss widens to Rs 142 Crore; IHH transaction to be completed shortly

      Fortis Q2 net loss widens to Rs 142 Crore; IHH transaction to be completed shortly

      Medical Dialogues Bureau10 Nov 2018 10:30 AM IST
      New Delhi: Fortis Healthcare has recently reported widening of its consolidated net loss to Rs 142 crore for the quarter ended September 2018, mainly...
      Strides subsidiary inks pact with SUDA Pharmaceuticals for migraine drug

      Strides' subsidiary inks pact with SUDA Pharmaceuticals for migraine drug

      Medical Dialogues Bureau10 Nov 2018 10:00 AM IST
      Sumatriptan is one of the most widely used drugs for the treatment of an acute migraine in adults. SUD-001H is a first-in-class mint-flavoured oral...
      Novartis division Sandoz recalls one lot of Losartan drug

      Novartis division Sandoz recalls one lot of Losartan drug

      Medical Dialogues Bureau10 Nov 2018 9:45 AM IST
      New Delhi: Novartis has recently announced its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen...
      Fortis Healthcare CEO Bhavdeep Singh quits

      Fortis Healthcare CEO Bhavdeep Singh quits

      Medical Dialogues Bureau9 Nov 2018 1:14 PM IST
      New Delhi : Fortis Healthcare said Thursday its CEO Bhavdeep Singh has resigned but will continue in his current capacity till a successor is found....
      Glenmark ties up with South Koreas SCD for ophthalmic products

      Glenmark ties up with South Korea's SCD for ophthalmic products

      Medical Dialogues Bureau9 Nov 2018 10:00 AM IST
      According to the pact, Glenmark and SCD will develop and commercialise six ophthalmic products in the US and Canada.New Delhi: Glenmark...
      Lilly to consider more acquisitions like Rs 115 Crore Armo buy

      Lilly to consider more acquisitions like Rs 115 Crore Armo buy

      Medical Dialogues Bureau9 Nov 2018 9:40 AM IST
      New Delhi: Eli Lilly and Co will consider more acquisitions similar to its $1.6 billion purchase of cancer drug developer Armo Biosciences earlier...
      AstraZeneca sells older asthma, rhinitis drugs for $350 mln

      AstraZeneca sells older asthma, rhinitis drugs for $350 mln

      Medical Dialogues Bureau9 Nov 2018 9:05 AM IST
      LONDON: AstraZeneca is selling three older drugs for asthma and rhinitis for at least $350 million as the company continues a strategy of divesting...
      NPPA fixes ceiling price of Nitrous Oxide, Oxygen, Details

      NPPA fixes ceiling price of Nitrous Oxide, Oxygen, Details

      Medical Dialogues Bureau8 Nov 2018 3:01 PM IST
      Through a recent notification NPPA, Department of pharmaceuticals has fixed the ceiling price of Nitrous oxide as well as oxygen. The ceiling...
      NBCC inks pact with Health Ministry to buy out HSCC

      NBCC inks pact with Health Ministry to buy out HSCC

      Medical Dialogues Bureau8 Nov 2018 10:00 AM IST
      In September, NBCC had said it will buy out the government's stake in consultancy firm HSCC for Rs 285 crore.New Delhi: State-owned NBCC has recently...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok